ES3007212T3 - Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease - Google Patents

Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease Download PDF

Info

Publication number
ES3007212T3
ES3007212T3 ES20708283T ES20708283T ES3007212T3 ES 3007212 T3 ES3007212 T3 ES 3007212T3 ES 20708283 T ES20708283 T ES 20708283T ES 20708283 T ES20708283 T ES 20708283T ES 3007212 T3 ES3007212 T3 ES 3007212T3
Authority
ES
Spain
Prior art keywords
migalastat
salt
patient
use according
cbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20708283T
Other languages
English (en)
Spanish (es)
Inventor
Nina Skuban
Hjalmar Lagast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69726736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3007212(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ES3007212T3 publication Critical patent/ES3007212T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES20708283T 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease Active ES3007212T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22
PCT/US2020/014531 WO2020154354A1 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease

Publications (1)

Publication Number Publication Date
ES3007212T3 true ES3007212T3 (en) 2025-03-19

Family

ID=69726736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20708283T Active ES3007212T3 (en) 2019-01-22 2020-01-22 Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease

Country Status (17)

Country Link
US (1) US20220087993A1 (enExample)
EP (2) EP4523750A3 (enExample)
JP (2) JP7680356B2 (enExample)
AR (1) AR117861A1 (enExample)
DK (1) DK3914247T3 (enExample)
ES (1) ES3007212T3 (enExample)
FI (1) FI3914247T3 (enExample)
HR (1) HRP20250078T1 (enExample)
HU (1) HUE069934T2 (enExample)
LT (1) LT3914247T (enExample)
PL (1) PL3914247T3 (enExample)
PT (1) PT3914247T (enExample)
RS (1) RS66410B1 (enExample)
SI (1) SI3914247T1 (enExample)
SM (1) SMT202500034T1 (enExample)
TW (1) TW202042812A (enExample)
WO (1) WO2020154354A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients

Also Published As

Publication number Publication date
HUE069934T2 (hu) 2025-04-28
LT3914247T (lt) 2025-01-27
EP3914247A1 (en) 2021-12-01
EP4523750A2 (en) 2025-03-19
PT3914247T (pt) 2025-01-23
JP2022518733A (ja) 2022-03-16
FI3914247T3 (fi) 2025-02-16
RS66410B1 (sr) 2025-02-28
US20220087993A1 (en) 2022-03-24
WO2020154354A1 (en) 2020-07-30
PL3914247T3 (pl) 2025-04-14
EP4523750A3 (en) 2025-06-11
SI3914247T1 (sl) 2025-03-31
AR117861A1 (es) 2021-09-01
JP2025128105A (ja) 2025-09-02
HRP20250078T1 (hr) 2025-03-28
EP3914247B1 (en) 2024-11-13
JP7680356B2 (ja) 2025-05-20
SMT202500034T1 (it) 2025-03-12
DK3914247T3 (da) 2025-01-27
TW202042812A (zh) 2020-12-01

Similar Documents

Publication Publication Date Title
ES3013820T3 (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
ES2993833T3 (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
ES2969263T3 (es) Tratamiento de pacientes con enfermedad de Fabry clásica con migalastat
ES3013813T3 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40124728A (en) Methods of reducing cerebrovascular events in patients with fabry disease
BR112020003974B1 (pt) Métodos para intensificar e/ou estabilizar função cardíaca em pacientes com doença de fabry